We previously reported that NCTD has multiple antitumor activities against different tumor cells [9, 12, 51, 61, 63], whereas Sorafenib is an oral multi-kinase inhibitor that blocks proliferation and carcinogenesis of different tumor cells including colonic adenocarcinoma cells by a dual mechanism including targeting several receptor tyrosine kinases such as VEGFR-2 and VEGFR-3 [37, 38]. This evidence concerns the gene FLT4 and colon adenocarcinoma.